Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Endometrial02 adjuvant T-DXd versus standard chemotherapy in HER2-expressing endometrial cancer
MOH_2025-12-14_015541Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo, Inc
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in endometrial cancer (EC) (2 arms), sponsored by Daiichi Sankyo, Inc. Primary endpoint: Disease-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2025-12-14_015541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-14_015541.